Adnan Younus, MD
Internal Medicine · Salisbury, MDNPI 1811413396
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AstraZeneca at 27.6% of the total. Reporting peaked in 2022 at $949 and has fallen 54.3% since, to $434 in 2025.
Across 177 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$872
- E.r. Squibb & Sons, L.L.C.$639
- Johnson & Johnson$385
- Novartis$374
- Pfizer$210
- Novo Nordisk$172
- plus $506 from 14 others
What the payments were for
- Food & beverage$3,160100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $872 |
| E.r. Squibb & Sons, L.L.C. | 53 | $639 |
| Johnson & Johnson(2 entities) | 22 | $385 |
| Novartis | 19 | $374 |
| Pfizer | 10 | $210 |
| Novo Nordisk | 10 | $172 |
| Gilead | 6 | $114 |
| Ceribell, Inc. | 4 | $68 |
| Lexicon Pharmaceuticals, Inc. | 3 | $48 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $40 |
| Janssen Scientific Affairs, LLC | 2 | $38 |
| UCB, Inc. | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Abbott | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $15 |
How this compares
$3,160 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $55 |
| ClopidogrelClopidogrel Bisulfate | 11 | $25 |
| Amlodipine Besylate | 12 | $19 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Salisbury
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
- Matthew MintzBethesda$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.